Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Difamilast - Otsuka Pharmaceutical

Drug Profile

Difamilast - Otsuka Pharmaceutical

Alternative Names: MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Acrotech Biopharma; Medimetriks Pharmaceuticals; Otsuka Beijing Research Institute; Otsuka Pharmaceutical Development & Commercialization
  • Class Benzamides; Nonsteroidal anti-inflammatories; Oxazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis

Most Recent Events

  • 29 Nov 2023 Otsuka Pharmaceutical completes a phase-III clinical trials in Atopic dermatitis (In infants) in Japan (Topical) (NCT05372653)
  • 27 Oct 2023 Acrotech Biopharma completes a phase III trial in Atopic dermatitis (In adolescents, In children, In adults, In the elderly) in USA (Topical) (NCT05608343)
  • 06 Feb 2023 Phase-III clinical trials in Atopic dermatitis (In adolescents, In adults, In the elderly) in China (Topical) (NCT05667623)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top